What is Aedicell?
Aedicell is at the forefront of developing safe and effective therapies for damaged tissue, particularly focusing on ulcers and chronic wounds. Their innovative technology leverages human amnion/chorion, umbilical cord, and placental disk tissue to create products that offer superior therapeutic value. Designed for ease of use and cost-effectiveness, Aedicell's solutions aim to provide healthcare providers with superior outcomes in wound management, positioning them as a key player in the medical technology sector.
How much funding has Aedicell raised?
Aedicell has raised a total of $93K across 1 funding round:
Debt
$93K
Debt (2021): $93K with participation from PPP
Key Investors in Aedicell
PPP
Public-Private Partnership
What's next for Aedicell?
With the recent influx of substantial expansion capital, Aedicell is poised for significant scaling and market penetration. The company's focus on innovative, cost-effective wound care therapies suggests a strategic push to broaden its reach within the healthcare provider network. This funding will likely fuel further research and development, enhance manufacturing capabilities, and support expanded commercialization efforts, solidifying Aedicell's position in the competitive wound care market.
See full Aedicell company page
